SEC Tracker
Get the app
QCLS · XBRL financial data

Q/C Technologies financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal years (QCLS's year ends in late December)

In thousands of dollarsDec 31, 2020Dec 31, 2021Dec 31, 2022†Dec 31, 2023Dec 31, 2024Dec 31, 2025
Research and development7,9646,7459,0677,8683,4413,472
General and administrative4,2996,4205,5205,4434,1623,737
Operating income (loss)(12,286)(28,810)(15,283)(17,123)(10,169)(9,847)
Net income (loss)(17,581)(29,889)(15,197)(4,000)(23,359)(11,627)
Earnings per share, basic USD per share—(0.85)(0.39)(5.33)(11.15)(8.66)
Earnings per share, diluted USD per share——(11.74)(5.33)(11.15)(8.66)
Weighted average shares, basic thousands of shares—35,01738,8261,5422,4371,730
Weighted average shares, diluted thousands of shares——1,2941,5422,4371,730
  • † Share count changed about 1/18 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal years (QCLS's year ends in late December)

In thousands of dollarsDec 31, 2020Dec 31, 2021Dec 31, 2022†Dec 31, 2023Dec 31, 2024Dec 31, 2025
Cash and cash equivalents18,6185567492,681173987
Marketable securities16,71811,0034,0872,2428,34514,801
Inventory198—————
Total current assets36,84312,6655,4025,8169,41216,581
Right-of-use asset5271491404711—
Goodwill—10,49910,49910,49910,49910,499
Total assets36,84324,81317,54017,86221,42141,166
Accounts payable2,2049872,6733,7162,9022,445
Accrued liabilities124119317637387383
Total current liabilities2,2631,0402,7694,9886,7015,532
Lease liability, non-current529676———
Total liabilities2,2631,1662,8455,0896,70116,441
Accumulated deficit(137,164)(78,562)(93,759)(101,977)(129,138)(144,123)
Total stockholders' equity34,57923,64714,69512,3709,79021,752
Total liabilities and equity36,84324,81317,54017,86221,42141,166
Common shares outstanding (cover page) thousands of shares16,65338,05839,4702,15810,1337,853
  • † Share count changed about 1/18 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal years (QCLS's year ends in late December)

In thousands of dollarsDec 31, 2020Dec 31, 2021Dec 31, 2022†Dec 31, 2023Dec 31, 2024Dec 31, 2025
Net income (loss)(17,581)(29,889)(15,197)(4,000)(23,359)(11,627)
Stock-based compensation855—6953,0501,0572,175
Depreciation and amortization29—————
Net cash from operating activities(11,925)(19,516)(12,270)(12,981)(8,976)(9,066)
Net cash from investing activities(8,757)19,8516,9131,846(6,101)(8,424)
Proceeds from issuing common stock29,184—5,550———
Net cash from financing activities38,668745,55013,06712,57018,304
Net change in cash17,9854081931,932(2,508)814
  • † Share count changed about 1/18 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2835 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2835 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Q/C Technologies308not reported(1,819)*8.2M6.0 quarters 10-QJun 30, 2026
Polomar Health Services1791,529121*28.4M— 10-QJun 30, 2026
Enveric Biosciences8,296not reported(2,445)*4.5M3.4 quarters 10-QJun 30, 2026
Jaguar Health3,7881,225(5,338)*not reported0.7 quarters 10-QJun 30, 2026
Integrated Biopharma4,471not reported(1,194)*31.1M3.7 quarters 10-KJun 30, 2026
Theriva Biologics11,3370*(3,085)*45.9M3.7 quarters 10-QJun 30, 2026
PTC Therapeutics508,894357,807(25,311)*83.5M— 10-QSep 30, 2026
Inhibitor Therapeutics516not reported(775)*173.8M0.7 quarters 10-QJun 30, 2026
Healthy Extracts1902,067306*14.7M— 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.